Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Zaqout et al.,
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate..,
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 (date from earlier preprint)
Retrospective 345 sotrovimab treated patients in Qatar matched with 583 patients that opted not to receive treatment, showing higher progression with treatment, without statistical significance.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 [Liu, Sheward, VanBlargan] and a lack of efficacy for BA.2 [Zhou]. US EUA has been revoked.
risk of progression, 164.7% higher, RR 2.65, p = 0.19, treatment 4 of 345 (1.2%), control 3 of 583 (0.5%), adjusted per study, odds ratio converted to relative risk, progression to severe/critical disease or mortality.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Zaqout et al., 21 Apr 2022, retrospective, Qatar, peer-reviewed, median age 40.0, 17 authors, study period 20 October, 2021 - 28 February, 2022.
Contact:
azaqout@hamad.qa, lja2002@qatarmed.cornell.edu.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Effectiveness of the neutralizing antibody sotrovimab among highrisk patients with mild to moderate SARS-CoV-2 in Qatar
Ahmed Zaqout,1,2* Muna A. Almaslamani,1,2 Hiam Chemaitelly,3,4,5 Samar A. Hashim,1,2
Ajithkumar Ittaman,1,2 Abeir Alimam,1,2 Fatma Rustom,1,6 Joanne Daghfal,1 Mohammed
Abukhattab,1,2 Sawsan AlMukdad,3,4 Anvar Hassan Kaleeckal,7 Ali Nizar Latif, 7 Adeel A.
Butt,2,5,10 Roberto Bertollini,8 Abdullatif Al-Khal,1,2 Ali S. Omrani,1,2 and Laith J. AbuRaddad3,4,5,9*
1
Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar
Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha,
Qatar
3
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University,
Doha, Qatar
4
World Health Organization Collaborating Centre for Disease Epidemiology Analytics on
HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar,
Cornell University, Qatar Foundation – Education City, Doha, Qatar
5
Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New
York, New York, USA
6
Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha,
Qatar
7
Hamad Medical Corporation, Doha, Qatar
8
Ministry of Public Health, Doha, Qatar
9
Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha,
Qatar
10
Department of Medicine, Weill Cornell Medicine, New York, NY and Doha, Qatar
2
*
Correspondence to Dr. Ahmed Zaqout, Hamad Medical Corporation, P.O. Box 3050, Doha,
Qatar, e-mail: azaqout@hamad.qa
Word count: Abstract: 50 words, Main Text: 1,499 words.
Number of tables: 1.
Running head: Real-world effectiveness of sotrovimab in Qatar.
Keywords: COVID-19; SARS-CoV-2; sotrovimab, Omicron; BA.2; variant; subvariant; casecontrol; epidemiology.
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Abstract
Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar
using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence.
Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those
sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91).
2
medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Several monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have been developed for..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit